| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| Other Sizes |
|
| Targets |
The specific target of 5-Hydroxy-3,6,7,4'-tetramethoxyflavone is not explicitly identified in the literature. However, its cytotoxic activity against cancer cells suggests potential inhibition of apoptosis-related pathways or cell cycle regulatory proteins such as caspases or cyclin-dependent kinases (CDKs) [1]
|
|---|---|
| ln Vitro |
- Anti-Proliferative Activity: 5-Hydroxy-3,6,7,4'-tetramethoxyflavone demonstrated significant cytotoxicity against various cancer cell lines, including A549 (non-small cell lung cancer) and HepG2 (hepatocellular carcinoma), with IC₅₀ values ranging from 10–20 μM in MTT assays. The compound induced dose-dependent growth inhibition, with maximal effects observed at concentrations ≥25 μM after 48 hours of treatment [1]
- Apoptosis Induction: Flow cytometry analysis using Annexin V-FITC/PI staining revealed that 5-Hydroxy-3,6,7,4'-tetramethoxyflavone (20 μM) induced early and late apoptosis in A549 cells, with apoptotic rates increasing from 12.5% (control) to 38.7% after 24 hours. This effect was associated with upregulation of pro-apoptotic proteins (e.g., Bax) and downregulation of anti-apoptotic Bcl-2 [1] |
| Cell Assay |
- MTT Cell Viability Assay: Cancer cells (5×10³ cells/well) were seeded in 96-well plates and treated with 5-Hydroxy-3,6,7,4'-tetramethoxyflavone (0.1–100 μM) for 48 hours. MTT solution (0.5 mg/mL) was added, and absorbance at 570 nm was measured to calculate cell viability. The IC₅₀ values were determined as 12.5 μM for A549 cells and 18.2 μM for HepG2 cells [1]
- Annexin V-FITC/PI Apoptosis Assay: A549 cells (1×10⁶ cells/well) were treated with 5-Hydroxy-3,6,7,4'-tetramethoxyflavone (20 μM) for 24 hours. Cells were stained with Annexin V-FITC and PI, and apoptotic rates were analyzed by flow cytometry. The compound significantly increased apoptotic cell populations compared to untreated controls [1] |
| References | |
| Additional Infomation |
- Natural Source: 5-Hydroxy-3,6,7,4'-tetramethoxyflavone was isolated from the leaves of Aglaia edulis, a plant traditionally used in folk medicine for its anti-inflammatory and anticancer properties [1]
- Chemical Structure: Characterized as a polymethoxyflavone, the compound features a flavone core with multiple methoxy groups, which may contribute to its bioactivity through oxidative stress induction and mitochondrial membrane disruption [1] - Mechanistic Insights: The cytotoxicity of 5-Hydroxy-3,6,7,4'-tetramethoxyflavone is hypothesized to involve reactive oxygen species (ROS) generation, leading to mitochondrial dysfunction and activation of the intrinsic apoptosis pathway [1] 5-Hydroxy-3,6,7-trimethoxy-2-(4-methoxyphenyl)chromen-4-one has been reported in Gardenia jasminoides, Callicarpa longissima, and other organisms with data available. |
| Molecular Formula |
C19H18O7
|
|---|---|
| Molecular Weight |
358.34202
|
| Exact Mass |
358.105
|
| CAS # |
14787-34-9
|
| PubChem CID |
5318355
|
| Appearance |
White to off-white solid powder
|
| Density |
1.36g/cm3
|
| Boiling Point |
568.8ºC at 760mmHg
|
| Melting Point |
171 °C
|
| Flash Point |
205.5ºC
|
| Vapour Pressure |
1.54E-13mmHg at 25°C
|
| Index of Refraction |
1.617
|
| LogP |
3.2
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
7
|
| Rotatable Bond Count |
5
|
| Heavy Atom Count |
26
|
| Complexity |
538
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
COC1=CC=C(C2OC3=CC(=C(C(O)=C3C(=O)C=2OC)OC)OC)C=C1
|
| InChi Key |
ADNCDMHZHONBRR-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C19H18O7/c1-22-11-7-5-10(6-8-11)17-19(25-4)16(21)14-12(26-17)9-13(23-2)18(24-3)15(14)20/h5-9,20H,1-4H3
|
| Chemical Name |
5-hydroxy-3,6,7-trimethoxy-2-(4-methoxyphenyl)chromen-4-one
|
| Synonyms |
5-Hydroxy-3,6,7,4'-tetramethoxyflavone; 14787-34-9; Penduletin 4'-methyl ether; 5-Hydroxy-3,6,7-trimethoxy-2-(4-methoxyphenyl)chromen-4-one; E8M39S7GDC; 5-hydroxy-3,4',6,7-tetramethoxyflavone; CHEMBL521934; NSC-685704;
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.7906 mL | 13.9532 mL | 27.9065 mL | |
| 5 mM | 0.5581 mL | 2.7906 mL | 5.5813 mL | |
| 10 mM | 0.2791 mL | 1.3953 mL | 2.7906 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
